Acceleration of NLRP3 inflammasome by chronic cerebral hypoperfusion in Alzheimer’s disease model mouse
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Neuroscience Research
- Vol. 143, 61-70
Abstract
No abstract availableKeywords
Funding Information
- Hirose International Scholarship Foundation
This publication has 23 references indexed in Scilit:
- Caspase-1: is IL-1 just the tip of the ICEberg?Cell Death & Disease, 2012
- Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disordersNature Reviews Neuroscience, 2011
- Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine ReceptorsJournal of Biological Chemistry, 2010
- Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat modelNeuroscience Research, 2008
- The NALP3 inflammasome is involved in the innate immune response to amyloid-βNature Immunology, 2008
- Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam studyAnnals of Neurology, 2005
- Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbitsBrain Research, 2005
- Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicityBiochemical and Biophysical Research Communications, 2004
- Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002